ViaCyte Revenue and Competitors

Claim your profile

Location

$289.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ViaCyte's estimated annual revenue is currently $22.5M per year.(i)
  • ViaCyte received $80.0M in venture funding in November 2018.
  • ViaCyte's estimated revenue per employee is $155,000
  • ViaCyte's total funding is $289.5M.

Employee Data

  • ViaCyte has 145 Employees.(i)
  • ViaCyte grew their employee count by 24% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$202.6M1397N/AN/AN/A
#2
$3.1M2018%N/AN/A

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability.  The second product is called the PEC-Encap (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease. www.viacyte.com

keywords:Biotechnology,Healthcare,Pharmaceuticals

$289.5M

Total Funding

145

Number of Employees

$22.5M

Revenue (est)

24%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ViaCyte News

2021-06-09 - ViaCyte Scores $45M For Stem Cell Therapy

San Diego-based ViaCyte, a company which is using stem cell technology to develop treatments for Type 1 Diabetes, says it has raised $45M in an extension of its Series D funding round. The funding brings its Series D funding to more than $115M. The funding came from existing investors Bain Capit ...

2021-06-19 - ViaCyte Raises $45M in Funding

ViaCyte, a San Diego CA-based regenerative medicine company, raised $45M in Series D funding. The round, which brought total Series D to more than $115m, includes participation from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management, Sanderling Ventures, Adage Cap ...

2021-06-30 - ViaCyte Raises $115 Million Series D

ViaCyte, a clinical stage biotech company, has raised $115 million in Series D financing, to bring forward two phase 2 studies of type 1 diabetes candidates. Michael Yang, President and CEO, ViaCyte The round includes participation from existing investors Bain Capital Life Sciences, TPG Capital ...

09/07/2019 - Vertex spends nearly $1bn on Semma's unproven diabetes ...

The only group to have reached the clinic with a similar approach, Viacyte, has had extremely mixed results (Regenerating insulin-producing ...

09/08/2019 - Global Pancreatic Beta-Cell Protection Market Analysis ...

Global Pancreatic Beta-Cell Protection Market Analysis, Growth, Demand, Study & Forecast-2019-2025: ViaCyte, PharmaCyte Biotech, ...

09/05/2019 - ?Global Pancreatic Beta-Cell Protection Market Strategic ...

Company profile section of players such as ViaCyte, PharmaCyte Biotech, Boehringer Ingelheim, GalaxoSmithKline, Beta-Cell NV, Novartis, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.4M14532%$321M
#2
$42.1M145-7%$26M
#3
$32.7M1452%$105M
#4
$23.9M145N/AN/A
#5
$39.9M145-17%N/A

ViaCyte Funding

DateAmountRoundLead InvestorsReference
2001-10-04$7.0MBArticle
2001-12-19$4.0MStrategic InvestmenSurModicsArticle
2003-05-05$UndisclosedDMultipleArticle
2007-07-17$25.0MCJohnson and Johnson DevelopmenArticle
2013-07-11$10.6MUndisclosedArticle
2014-02-07$7.0MUndisclosedJDRFArticle
2014-08-11$5.4MC-1Article
2014-08-26$20.0MUndisclosedJanssen Research & Development LLCArticle
2017-05-23$10.0MUndisclosedAsset Management Partners,Article
2018-11-30$80.0MDBain Capital Life SciencesArticle